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Abstract
Background: The history of psoriasis, remains highly speculative for the time before Willan (1757-
1812), and can be reliably assigned only for the last 200 years. Terms such as "Leprosy", "Impetigo"
and "Psora" have been used in the centuries before. Hebra (1806-1880) gave a morphological and
nosologic definition, in which also the histopathology appearance was taken into account. In the
early 20th century, it was the biochemistry and histochemistry, which provided new insights. In the
second half of the 20th century, immunocytochemistry and immunology shed some light on the
pathogenetic processes of the disease. At the end of the 20th and at the beginning of the 21st
century, it is the triumph of genetics and immunology, which have opened new therapeutic
possibilities due to the interesting insights into the pathogenesis of psoriasis. However besides the
new therapeutic modalities, which harbor some health and some economic threats, classical
approaches still remain valuable tools.
Introduction
Psoriasis is one of the most common diagno-
ses in dermatology; therefore it is justified to
provide some information on the historical
background of this frequent disease.
One has to admit however, that talking about
historical aspects of diseases and especially
of dermatoses is always somehow specula-
tive. It is clear, that most of the diseases we
see today already existed 2000 and more
years ago and one has to be aware of the fact,
that legends and mystery easily melt into
“history”. The perception of the diseases in
ancient time was rather religious or mysteri-
ous than scientific, as we see it today. 
Much has been written about the history of
psoriasis, which roughly can be divided into
3 periods, looking back 2000 years, 200 years
and to the past 20 years.
The following citations characterize the chal-
lenge, which psoriasis imposed  and still does
on physicians and patients: William James
Erasmus Wilson (1809 – 1884) stated «…it is
not a disease, on which to build a medical re-
putation…» and Paul Bechet, New York (1936)
pointed out that «Psoriasis is an antidot for
dermatologists’ ego. » (cited from [1])
There are several reviews, on the subject,
which have been a major resource for this re-
view article [2, 3, 4, 5, 6, 7].
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Ancient Times: Egypt, Greece and Rome
In Ancient Times diseases were deemed an
individual punishment for blasphemic
conduct of life or a consequence of low
sanitation and hygiene. “Psoriasis” at that time
like other diseases was an issue of ignorance,
confusion of nomenclature and terminology
When looking 2 or 3’000 years back, religious
texts sometimes may give interesting views or
at least some arguments for speculations. 
In one of the most famous documents
conserved today, the Ebers Papyrus (around
1500 BC), do not mention Psoriasis but give
some remedies for treating skin diseases in
general.
Hippocrates (460-370 BC) refers to “impetigo”
without specific mentioning of psoriasis even
though he must have seen the disease. 
Aulus Cornelius Celsus (25BC-50 AD), who
probably was not a physician, but a roman
enzyclopedian, in his “De Re Medica Libri
Octo” describes psoriasis, but calls it
“impetigo”.
The “Corpus Galenicum” was the basis for
teaching and learning medicine over centuries.
Galen (133-200) introduced the term
«psoriasis» to designate diseases (scaling of
eyelids and scrotum with erosions; seborrhoeic
eczema?), entirely different from psoriasis.
Medieval Ages from 6th till 15th Century 
In the Medieval Ages (600 – 1500 AC), Avi-
cenna (Ibn Sina) (980-1037) - a Persian physi-
cian, physicist, scientist and philosopher-
was the most influential representative of Me-
dieval medicine. His encyclopaedic Canon of
Medicine, completed in 1025, comprises five
books compiling the medical knowledge of the
time. It is considered one of the most famous
books in the history of medicine and it provi-
ded the basis for teaching and learning me-
dicine not only in the orient but also in
Europe. It also contains the first careful des-
cription of skin diseases. Avicenna very much
followed Galen.
Hildegard von Bingen (1098 – 1179) was a in-
subordinate Abbess and polymath ( music,
natural sciences, medicine, theology). She
used to pass out if she wanted to pursue her
aims against the opposition of the authorities.
The medical treatise ascribed to Hildegard
were Causae et Curae (causes  and treat-
ments) and Physica, in which she compiles
the folk and monastic medicine of her time
using herbs, stones and animals on the prin-
ciple of contraries (contraria contrariis curan-
tur) for the treatment  of diseases [8].
She differentiates various types of “Lepra“
(skin rashes, most probably including “pso-
riasis”) caused either due to acoria and drun-
kenness or due to irascibility and “Lepra
contagiosa sanabilis” due to lasciviousness. 
The first universities and medical schools
were founded in Europe in Salerno, Bologna,
Montpellier, Paris and Oxford in the 12th and
13th century. Little attention was attributed
to changes of the skin, which still at that time
in the context of “humoral medicine” were
thought to be just an “excretion organ” rather
than the manifestation of diseases. Paintings
from that time do not show specific skin lesi-
ons but just dots and spots on or within the
skin
In “De morbis cutaneis, et omnibus corporis
humani excrementis tractatus locupletissimi”
(Venedig 1572)  Girolomo Hironymus Mercu-
rialis (1530-1606) classifies diseases of the
skin according to their localisation [1] in the
head and neck or [2] at other sides of the
body. He paid little attention to morphology
of the single lesions and described psoriasis
under the name of “lepra grecorum” and for
other conditions used the term “psora”(itch)
[9].
The first ones to look for morphology of skin
changes and probably showing psoriasis for
the first time were artists, like Ferdinand Bol,
a flamish painter, who in his work “The Di-
rector of the Lepra House in Amsterdam” de-
picted the social situation of a young boy
showing his capillitium covered with dense
white scales, which from a medical point of
view today might be interpreted as psoriasis
or rather as Favus (Figure 1) [10].
In summary, in the Middle Ages there was no
scientific pathogenetic or morphologic per-
ception of the disease, we refer to today as
psoriasis and we should be cautious in over-
interpreting descriptions from this time.
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Figure 1. Ferdinand Bol (1616 –
1680). The Director of the Lepra-
House in Amsterdam. Le Petit Pa-
lais, Paris. Lepra or Favus on the
capillitium of a young boy
The Beginning of Academic Dermatology
in the 18th Century
Josef Plenck (1735-1807), was an Austrian
surgeon and obstetrician. In his book “Doct-
rina de Morbis Cutaneiis” (1776) [11] he clas-
sified 120 skin diseases into 14 classes based
on the works of Carl von Linné (1707-1778)
and Francois Boissier de Sauvages de la Lac-
roix (1707-1767). Some remarks in Class VI:
Lepra crustosa and in Class VII about squa-
mous diseases might refer to psoriasis, [11] 
Robert Willan’s  (1757-1812) [12] improved
the classification of skin disorders based on
morphologic criteria of Joseph Jakob Plenck
(1735-1807) [11]. The second of the 8 classes
in his treatise dealt with “Scales” (Figure 2).
He differentiated psoriasis from leprosy
(psora leprosa and lepra grecorum) and  des-
cribed different forms of psoriasis: guttata,
diffusa, gyrata, palmaria, unguium, invete-
rata. He also noticed that the disease begins
on the knees and elbows, attacks the scalp
and also the finger and toe-nails [9]. In his
book there we find the first medical painting
of lepra vulgaris that can be identified as pso-
riasis. (Quelle: Willan, Robert: “Description
and Treatment of Cutaneous Diseases” Order
I. papulous eruptions, London 1798)
Charles Anne Lorry (1726-1783) was a con-
temporary of Willan and a physician of Louis
XVI. In his book «Tractatus de morbis cuta-
neis» he presents an etiologic classification of
dermatoses, mentioning also a phenomenon,
later described by Carl Heinrich Auspitz
(1835-1886) [13].
Another contemporarian of Willan, was Baron
Jean Loius Alibert (1768-1837) in Paris. He
tried to consider morphologic, pathogenetic,
metabolic and other aspects in order to create
a systemic, kind of pattern-organization of di-
seases of the skin. However the result, the
“Arbre de Diagnoses” generated a big confu-
sion, placing “psoriasis” as “dartre squa-
meuse” besides other “dartres”. Wilkinson
(1822), an admirer of Willan commented Ali-
bert’s work with the following writing (cited
acc to [14]):  “From the perusal of Monsieur
Alibert's inflated fustian in his 'Description
des Maladies de la Peau' I rise, as I think
every sober man must rise, puzzled and dis-
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Figure 2. Willan, R. and T. Bateman (1813). A Practical Synopsis of Cutaneous Diseases. London. The second of
the 8 classes dealt with “Scales”
Table 1. Perception of “Psoriasis” through the Centuries
Ancient Hebrews (Old Testament)
Hippocrates








«lepra» covers various dermatoses including, ichthyosis, elephantiasis (true
lepra), vitiligo («alphos»), eczema, syphilis(?) and psoriasis
impetigo, no specific mentioning of «psoriasis» even though he must have
seen the disease
first description of psoriasis as second species of «impetigo»
introduced the term «psoriasis» to designate diseases (scaling of eyelids and
scrotum with erosions; seborrhoeic eczema?), entirely different from psoria-
sis
No clinico-morphologic description. «Leprosy» -like in ancient times- covered
various diseases 
no accurate description or differentiation
first morphologic description after Celsus and differentiation between true
leprosy and lepra vulgaris («Psoriasis»)
big confusion: names dartre sèche, dartre squameuse lichénoide and dartre
furfuracée.  Alibert» used the term psoride pustuleuse as a synonym for sca-
bies
one year before Hebra had stated, that lepra vulgaris is just another form
of psoriasis
eliminated the term “lepra” and gave a scientific conception to “psoriasis”
gusted; ... he has continued ... to render this
department of the science (Hôpital St. Louis
in Paris) more confused and incomprehen-
sible than he found it.”
The following table summarizes the history of
the perception of what today we refer to as
psoriasis [Table 1]
Prior to Hebra, the skin was seen as a place
for relief of bad fluids according to the con-
cept of humoralism and skin disorders were
not treated in order to let the bad fluids out. 
Ferdinand Hebra (1816-1880) (Figure 3), who
is deemed as the one of the “fathers” of der-
matology as a self-standing discipline, was a
surgeon. At the age of 29 he was appointed
chairman of the department of Dermatology,
which had been established by and for him.
He confirmed the high reputation of the Vi-
enna School for dermatology.
Hebra cut the Gordian knot and defined pso-
riasis as a distinct disease entity in 1841.
Hebra described many diseases and in self
experiments proved scabies to be exclusively
due to mites, which could be treated [15].
Variants, Diagnostic Signs and
Histopathology of Psoriasis
In the Atlas on Skin Diseases edited by Prin-
gle in 1897 [16]. Jacquet considers “psoriasis
figurate” a special disease, related to Unna’s
seborrhoeic eczema and to be different from
the psoriasis vulgaris, described and depicted
by Feulard in the same atlas.
Von Zumbusch observed a male patient, who
had had classic psoriasis for several years
and finally developed multiple pustules [17,
18]. Andrews at the Annual Session of the
American Medical Association in Milwaukee
1933 presented patients with pustular erup-
tions of the palms and soles and described fif-
teen cases [19], which had clinical features
similar to the description of pustular psoria-
sis of the extremities, given by Barber [20].
Heinrich Köbner (1838-1904), who 1861 foun-
ded his own Institute for Dermato-Venereo-
logy in Breslau, presented a case in whom
psoriatic lesions developed at the site of a bite
by a horse (isomorphic reaction) [21, 22] (cit
acc [23]). This observation initiated an in-
tense academic discussion on the impact of
external influences in the pathogenesis of
psoriasis.
The histologic hallmarks of psoriasis [Table
2] are known for >200 years. 
Carl Heinrich Auspitz (1835-1886) was an
Austrian dermatologist. He described and
explained the phenomenon, which is due to
the small bridge of epidermis above the pso-
riatic papillae [9].
Paul Gerson Unna (1850-1929) was one of the
first dermatopathologists. In his voluminous
book in a brief chapter on psoriasis he des-
cribes the basic characteristics of the disease
(parakeratosis, proliferation of the epidermis,
and changes of vessels) [24]. 
The 19th century  was the time, when great
progress in medicine came from great disco-
veries in microbiology: favus (Schönlein
1839), Lepra (Hansen 1872), gonorrhoea (Ne-
isser 1879), Tbc (Koch 1892), chancre (Ducrey
1889), syphilis (Schaudinn and Hoffmann
1905). In speculating about the pathogenesis
of psoriasis, Unna during his histopathologic
studies observed “micrococci” and commen-
ted his findings as follows: “«…unfortunately
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Figure 3. Ferdinand Hebra (1816-1880), the «Father of
Dermatology»
the sparseness of the micrococci in the horny
layer of psoriasis renders their identification
not impossible but difficult…». Unna’s obser-
vations however were critically questioned by
other investigators [25, 26].
Another histopathologic hallmarks of psoria-
sis are the intraepidermal microabscesses
and spongiform pustules, as described by the
Australian physician William John Munro
(1861-1908) in 1898 [27] (Figure 4) and
Franjo Kogoj (1894-1983) from Zagreb in
1928 respectively.
Woronoff at the department of dermatology in
Moscow described ring like anaemisation of
the skin around lesions of psoriasis and se-
condary syphilis, which he called “pseudoat-
rophic zones” [28] (Figure 5).
History of the Pathogenesis of Psoriasis
Like in other diseases, pathogenetic concepts
always have to be seen in the context of the
medical knowledge of the time, and techno-
logic and scientific progress [Table 3]. It
therefore is not surprising, that a decease
presenting with so many various clinical and
morphologic features like psoriasis has been
and still is a highly interesting issue for spec-
ulations as well as  for solid clinical and lab-
oratory investigations; even more since it got
clear, that psoriasis is not just a disease of
the skin but evolves on a systemic patho-
genetic background.
A genetic background already has been assu-
med for a long time (Wutzdorf [29], Köbner,
Hebra, cit acc [23]). More recent work has
shown that there are at least 2 genetic cons-
tellations: (1) a juvenile exanthematic form
and (2) an adult form which presents as large
stable plaques [30, 31].
Because of the symmetry of the disease, Prin-
gle and his contemporaries also thought of a
pathogenetic impact of the nervous system
[16].
A major breakthrough was the detection of
the acceleration of the epidermal turnover by
cytogenetic studies [32, 33].
Immunocytochemical studies in the 1970s
showed the involvement of dermal dendritic
cells (macrophages) [34]. and of prominent
blood vessels in the papillary dermis [35].
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Table 2. The Histologic Hallmarks of Psoriasis
*    Epidermal hyperproliferation with loss of proper stratified differentiation of the affected epidermis (parakerato-
sis)
*    Expansion of the dermal vascular bed, elongation and tortuous dilatation of postcapillary venules in the st. pa-
pillare
*    Accumulation of (T-) lymphocytes and other inflammatory cells (dendritic cells/macrophages) in both the dermis
and epidermis
Figure 4. Microabscess as described by Munro
in 1898 [27]
Figure 5. Woronoff-rings as schematically depicted in
his original paper on his observation [28]
Today there is significant evidence, that the
immune system plays an important role in
the pathogenesis of psoriasis [Table 4].
Evidence for the immunologic background
also came from accidental clinical observa-
tions or from clinical studies, in which pa-
tients with psoriasis responded well to
cytostatic or immunosuppressive drugs [36].
Looking for some review articles on psoriasis
during the past 20 years, the following cita-
tions in some way reflect the step by step
progress in our understanding of this multi-
faceted disease:
* 1995: “Recently, progress has been made in
understanding the pathogenesis of psoria-
sis… There is at present no cure, only sup-
pressive therapy… The presumptive
involvement of T cells in psoriasis is leading
to intense interest in immunotherapy…and in
identifying the genes (PSOR1)…  In the fu-
ture, psoriasis may be amenable to gene ther-
apy.” [37].
* 1999: “Therapies for psoriasis … tend to
have a remittent effect (inducing long-term
remission) or a suppressive effect (improving
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Table 3. History of the Pathogenesis of Psoriasis
Old age: no attention
Rome and Greece: dyscrasia of fluids (blood, yellow and black bile, slime), 
Middle Ages (500-1500). Little attention, mystification, «dark century» of science
19th century:
Genetic predisposition plus external factors (Wutzdorff 1876; Köbner 1872; Hebra1860)
Nervous origin (Pringle 1897)
20st century:
Cellular origin. Epidermal (cellcycle) vs dermal vs vascular and inflammatory (leucocytes) micro
environmental factors
Cytogenetic studies on epidermal turnover (v. Scott 1963, 1973, Weinstein 1978) 
1970 metabolic disorder (histochemistry, biochemistry)
1980 immunologic disorder





Table 4. Role of the Immune System in the Pathogenesis of Psoriasis
Increased 
Dendritic cells and IFN-alpha
T-cells
Th1-cytokines
Vascular endothelial growth factor (VEGF)
Cytokines
Therapeutic effect of PUVA 
Therapeutic effectivity of immunosuppressive drugs : cyclosporine (Müller 1979; Ellis et al 1991)                  
and Rifampicin (Tsankov 1993,2011)
Therapeutic effectivity of anti-CD4 (Morel et 1992)
Clearing after bone marrow transplantation
Transfer from transplant donor to recipient
lesions but with a prompt recurrence when
the treatment is discontinued)” [38].
* 2005: «The most promising compounds are
monoclonal antibodies, cytokines, and fusion
proteins» [39].
* “Numerous other biologic agents and im-
mune response modifiers are under develop-
ment; all of them use at least one of the
mechanisms mentioned above» (inhibition of
T-cell activation, depletion of pathogenic T-
cells, inhibition of leucocyte recruitment, cor-
rection of immune deviation)[39].
* 2009: “The evolution of a psoriatic lesion is
based on a complex interplay between envi-
ronmental and genetic factors that sets the
scene for disease initiating events.” [40]. 
* “…However, major issues remain unre-
solved, including the primary nature of the
disease as an epithelial or immunologic dis-
order, the autoimmune cause of the inflam-
matory process, the relevance of cutaneous
versus systemic factors, and the role of ge-
netic versus environmental influences on dis-
ease initiation, progression, and response to
therapy.” [40].
History of the Therapy of Psoriasis
It is an unwritten law in medicine that the
less understood a disease is the larger is the
list of our armamentarium for therapeutic ap-
proaches, which have been recommended
over the decades and centuries. This holds
true also for psoriasis as summarised in
[Table 5].
One of the most curious recommendations,
which are mentioned in the Ebers papyrus,
has been the use of excrements from cats and
dogs. In the Middle Ages a concoction from
snakes (Viper-broth) was applied and coal tar
which in some instances still may be an app-
ropriate remedy today and which already has
been recommended by Pedanios Dioscurides
(40-90 AD) from Anazarbos in Kilikien, which
belongs to Turkey today. He was a Greece mi-
litary physician, who served for Claudius and
Nero in Rome and was one of the most fa-
mous pharmacists of the antique. 
Arsenic (Asiatic pills and Fowler’s solution)
has been very effective in the treatment of
psoriasis and other diseases, including syphi-
lis. It has been used extensively during the
19th and first half of the 20st century, till the
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Table 5. Selection of Therapeutic Measurements From Ancient till Modern Time 
Ebers Papyrus (1500 BC): topical cats and dogs dung (faeces)
Galen: Viper-broth; Coal tar
Daniel Turner 1723: Galens remedy (boile viper-broth) and ammoniated mercury (topically)
Balmanno Squire 1876: Chrysarubin (Goa powder) 
Thomas Fowler. Solution of potassium arsenite 
Thomas Gridlestone 1806: Fowler’s solution in psoriasis
E. Tipp 1869: sc-injection of arsenous acid
Hebra and Kaposi: «Asiatic Pills»
Roentgentherapy for psoriasis in 1900 in Europe
1933 Low fat diet
1950 Sulzberger: Corticosteroids
1970-1990 UVA and PUVA
1990’s Vitamin D3
1990-2000 Immunological treatment modalities
1993, 2011 Tsankov: Rifampicin 
2000 on Biologicals 
hazardous effects of this substance got obvi-
ous.
Another treatment approach which still is
employed today is keeping diet. The rational
for this is the observation that during World
War II the incidence of psoriasis decreased
[41], the biochemical composition of psoriatic
scales and the high blood levels of cholesterol
and other lipids in the blood in patients with
psoriasis. This therapeutic approach was
supported by several laboratory investigati-
ons [42, 43].
Glucocorticosteroids (have revolutionized the-
rapy and early in time also have been used in
Dermatology, topically and systemically, alt-
hough the first reports on the topical use in
psoriasis were not very enthusiastic [44].
An early description of “balneotherapy” can
be found in the Old Testament (Lukas 4.27),
even though we do not know which skin di-
sease Naaman, the commander of the army
of the king of Arman was suffering from (the
term “Lepra” at this time covered many der-
matoses and there is a risk that this text was
ment as a methapher and did not describe an
practical treatment at all): “…so he (Naaman)
went down and dipped himself in the Jordan
seven times, as the man of God (Elisha) had
told him, and his flesh was restored and be-
came clean like that of a young boy.” [45].
For centuries in India chrysarobin (2-methyl
dithranol), the active ingredient of Goa-pow-
der (natural; synthetic: anthralin or cignolin)
was used for the treatment of “ringworm”
(dermatomycoses). The English physician
Balmanno Squire in 1876 inadvertently disco-
vered its use for psoriasis [9, 46]. 
Hippokrates and other ancient physicians
treated skin diseases with pine coal tar [47].
During the first half of the 20iest century it
was found to be particularly useful in psoria-
sis [48], either alone or in combination with
light and anthralin [49].
The mode of action of anthralins and coal tar
is not completely elucidated. They probably
function by retardation of the altered epider-
mal cell kinetics.
Arsenic and mercury have been used in order
to treat not only syphilis but also psoriasis.
Fowler’s solution containing 1% arsenic was
very effective [50].
The beneficial effect of aminopterin (Methot-
rexat) in psoriasis has been detected acciden-
tally when clearing in a patient treated for his
rheumatoid arthritis [51]. The approval by
the FDA for the use in psoriasis was given in
1972 [47].
Cyclosporine (Sandimmune) originally has
been developed to prevent rejection of organ
transplants. Like with methotrexate it was
fortuitously found to clear psoriasis in pati-
ents being treated for severe longstanding
rheumatoid arthritis [52]. In 1997 cyclospo-
rine was FDA approved for the treatment of
psoriasis [53].
Another less hazardous immunomodulator
recommended recently is Rifampicin [54].
Retinoids have been used for treatment of ke-
ratosis [55]. While first generation and
synthetic topical retinoids (1940ies) did not
have significant antipsoriatic activity, the ef-
ficacy of second generation retinoids
(1990ies), etretinate and its derivate acitretin
was much better [56].
Vitamin D and its analogues also were found
by chance to be beneficial in the treatment of
psoriasis in a patient who received Vitamin
D3 for the treatment of osteoporosis [57]. A
topical form of vitamin D has been formulated
for this indication [58].
At the end of the 19th century first reports of
UV-Light in the treatment of tuberculosis and
wound healing arouse interest in photothe-
rapy. At the same time sunlight as a natural
healing force became a main pier of the ari-
sing reform movement and naturopathy [59].
The photochemotherapy (PUVA, psoralen and
long wave ultraviolet light A) of psoriasis has
been reviewed in an autobiographically tinged
monography [5]. At least 3 roots can be follo-
wed: (1) Egypt [60]. Ammi majus or Bishop’s
weed has been recommended in the Ebers
papyrus (1’500 BC) to be rubbed directly into
the skin or taken orally and then to stand
naked in the sun (2) Europe. There have been
experiments in  Switzerland with selective
spectra of UV-light [61].  In Germany studies
with topical photosensitizers have been per-
formed [62, 63]. In Austria methoxsalen was
applied orally [64], following successful stu-
dies in (3) the United States [65]. 
A very special and regional approach to the
therapy of psoriasis is bathing with fishes
from Sivas-Kangal [66].
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An early immunologic approach to the treat-
ment of psoriasis was with monoclonal anti-
bodies [67]. The mode of action was
considered to be different from the pathway
in photochemotherapy: “We conclude that
anti-CD4 mAb administration can induce a
rapid and major improvement in psoriatic le-
sions (.. of 3 patients with severe psoriasis...),
with immunohistochemical changes different
from those induced by cyclosporin A or 8-
methoxypsoralen plus long wave UV light
(PUVA) therapy. Our data provide strong evi-
dence for a critical role of CD4+ lymphocytes
in psoriasis” [67].
Clinical observations and laboratory investi-
gations of the past decade have pointed to the
fact, that psoriasis is a T helper (Th)17/Th1-
mediated autoimmune disease affecting the
skin and joints [40]. Based on the understan-
ding of the immunologic processes, several
substances for a targeted therapy have been
developed (Biologicals) [68] and have been
approved by the FDA in 2003 for the treat-
ment of psoriasis [57].
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* Report on the treatment with retinoids, Methotrexate and light in the book “Self-consciousness: Memoirs”, 1976
** Movie: The singing Detective (trailer: http://www.youtube.com/watch?v=wwwhtUdGOVM) 
*** Suffered possibly from chronic eczema (neurodermatitis)
Figure 6. Historical view on evergreens, nevergreens and «dead end» therapies in psoriasis (not comprehensive)
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The many substances and procedures recom-
mended or used for the treatment of psoriasis
roughly can be designated as evergreens (suc-
cessful use up today), “nevergreens” (anecdo-
tic reports) and obsolete (including hazardous
substances like arsenic or mercury) (Figure
6). This review is not comprehensive and
many issues are missing. 
Famous Persons Suffering from Psoriasis
Psoriasis is one of the most frequent der-
matoses, affecting about 2% of the population,
including average people and celebrities, among
them artists, poets, revolutionizer,  politicians,
and others. Most of them tried to hide their dis-
ease. Only Dennis Potter very frankly presented
the psychological distress of his disease in the
Table 7. History of Psoriasis. Milestones and Protagonists
Old Age: Ignorance no scientific basis, skin rash and impurity, punishment by God 
Greece: Neglectance, Hippocrates (460-377): psora= itch
Roman Empire 1st Century: lack of consistent terms and nomenclature
Cornelius Celsus (25 BC-50): first description of psoriasis
Galen (131-201 AD): first use of the term psoriasis (probably for seborrhoeic dermatitis) 
Middle Age (500-1500): Neglectance, clerical mysticism. «Dark» age for Science 
Arabian Medicine (Avicenna 980-1037)
Early18th Century: «Protodermatologists»
Charles Anne Lorry (1726-1783): «Tractatus de morbis cutaneis». 
Joseph Jacob Plenck (1738-1807): Surgeon and obstetrician. Term Impetigo (Latin «atack»)
Late18th Century: «Dermatologists»: Nosologic Descriptions
Robert Willan (1757-1812): differentiation between psora leprosa and psora grecorum
Jean Louis Alibert (1768-1837): Psoriasis in the group of «dartrous dermatoses «
Early 19th Century: Nosologic definitions, impact of histopathology
Ferdinand Hebra (1806-1880): definitely separated psoriasis from leprosy; histopathology
Heinrich Auspitz (1835-1886): histopathology; sign already seen by Willan and Hebra
Ernest Henri Besnier (1831-1909): Histopathology; term «arthritis psoriatica»
William John Munro (1861-1908): Microabscess (1898)
Paul Gerson Unna (1850-1929): Histopathology; Micrococci
Late 19th and early 20st Century: Description of Variants of Psoriasis
Leo von Zumbusch (1884-1940): Psoriasis pustularis 1910
Königsbeck (1917), Barber (1936): Psoriasis pustulosa palmoplantaris
Heinrich Köbner (1838-1904): isomorphous effect of irritation
DL Woronoff (1926): rings around lesions  in psoriasis and in corymbiform syphilis
20st Century: Biochemistry, Histochemistry, Cytogenetics, PASI, Biologics
Carbohydrate Metabolism in psoriatic epidermis (Halprim, Vorhees, Rassner, Braun-Falco)
Epidermal turnover: van Scott, EJ, 1963,1973; Weinstein 1968
Multifactorial: different chromosomes (PSOR1-PSOR9)
HLA-association;Type 1 and Type 2 (Henseler and Christophers 1985)
PASI 1972 (Fredriksson and Pettersson)
Treatment with Biologics, anti CD4 1992
21st Century: Genetics, Immunology, Autoimmunity, Targeted Therapy (Biologics)
Mode of inheritance: chromosomal loci with linkage to psoriasis (PSOR1(Chr 6p)-PSOR9)
Dendritic cells and T-cells, type I interferons 
Dysregulated immune system in psoriasis; role of plasmacytoid dendritic cells, IFN-α
Antimicrobial peptides from keratinocytes: defensin, psoriasin (Schroeder) 
Alteration of the innate and adaptive immune response in psoriasis
Targeted therapy with biologics 
Future Issues: Safety, Economics; Controlled Studies; Psoriasis-Registries
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movie “The Singing Detective” (trailer:
http://www.youtube.com/watch?v=wwwh-
tUdGOVM).
An incomplete list of famous persons suffer-
ing from psoriasis is given in [Table 6].
Timeline of Psoriasis through the Ages
The time line over the centuries reflects a
cloudy image which has to be seen in the con-
text of the perception of diseases in the re-
spective time periods [Table 7].
There was ignorance no scientific basis on the
nature of the disease in ancient time and con-
fusion lack of consistent terms and nomen-
clature still through the Middle Ages. For the
first time, Lorry in France and Plenck in Aus-
tria, subsequently Alibert and Willan payed
more attention to the disease and defined it
as a nosologic entity, which finally was la-
belled with the term “psoriasis vulgaris” by
Hebra. Many important contributions on the
histopathologic changes came from Hebra,
Auspitz, Besnier, Munro, Unna, Kogoj and oth-
ers in the late 19th and early 20st century.
During the same time, some clinical variants
of psoriasis were described. Studies on pso-
riasis in the 20st century were driven by new
laboratory technologies (biochemistry, histo-
chemistry, immunohistochemistry), which all
generated some interesting results and fig-
ures, however without elucidating the basic
pathogenetic nature of the disease. Only the
last decade of the past and the first decade of
the 21st century shed some light on the com-
plex genetically predetermined and immuno-
logically driven systemic disease with its
major manifestation on the skin. These new
insights into the pathogenetic processes facil-
itated the development of targeted biologic
therapies. Since the new therapeutics are ex-
tremely expensive and also imply some
threats and side effects, a pivotal challenge
for the future will be controlled clinical stud-
ies on safety, efficiency and economic ac-
countability and collection of data in
“psoriasis registries”.
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